Liven Pharma to Raise Rs. 200 Million Through Rights Issue for Expansion
Liven Pharma Limited has announced plans to raise Rs. 200 million through a rights issue aimed at strengthening its financial position and funding business expansion.
The company informed the Pakistan Stock Exchange (PSX) that it will issue 20 million ordinary shares at Rs. 10 each, representing roughly 21.5% of its paid-up capital. Shareholders will receive 21.496 rights shares for every 100 ordinary shares held.
Use of Proceeds
The funds raised from the rights issue will be used to:
-
Support working capital needs
-
Finance capital expenditures
-
Develop a Dry Powder Injectables division
-
Procure vehicles
-
Cover costs related to Drug Regulatory Authority of Pakistan (DRAP) registration and licensing
The company emphasized that the issue price is set at face value, following market norms, and that major shareholders and directors have confirmed participation.
Liven Pharma expects the rights issue to enhance profitability and shareholder returns, while posing minimal investment risk, as the issue price is below the current market level.
The company’s primary business is manufacturing pharmaceuticals and allied products, and this capital infusion is aimed at supporting its growth and strategic expansion plans.
